However, until now, its most promising clinical application is in the treatment of tuberous sclerosis complex (TSC), a rare disease where a mutation of the TSC1 or TSC2 gene leads to overactivation of mTORC1, resulting in the growth of benign tumors in multiple organs including the brain, kidney, heart, and skin [7]. The gene discussed is TSC1; the disease is tuberous sclerosis.